Zacks Investment Research on MSN
ALT stock up 17% after pemvidutide gets FDA breakthrough tag for MASH
Altimmune ALT announced that the FDA has granted Breakthrough Therapy Designation to its lead pipeline candidate, pemvidutide ...
Stocktwits on MSN
Altimmune receives FDA’s breakthrough therapy designation for its liver disease drug
Altimmune, Inc. (ALT) announced on Monday that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation ...
MASLD is one of the pressing public health issues; yet, unfortunately, there is a scarcity of available pharmacological management options. GLP-1RAs have transformed the treatment landscape for ...
Peptide hormones and bile acids shaping immune tolerance of the liver: implications and applications
Though it has long been recognized that the liver exhibits remarkable immune tolerance, the underlying mechanisms driving ...
"MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial" was originally created and published by Clinical ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 73, No. 12 (Dec., 1976), pp. 4511-4515 (5 pages) Liver parenchymal cells were isolated from adult rats and ...
GAITHERSBURG, Md., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced a preclinical data presentation on ALT-801, its balanced ...
- Study results demonstrate DD01 was safe and well-tolerated at doses highly effective in reducing fatty liver. - Following only 4 weeks of treatment, all subjects in high dose group achieved at least ...
Glucose is the key source of energy for the human body. Supply of this vital nutrient is carried through the bloodstream to many of the body’s cells. The liver produces, stores and releases glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback